Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease

Inflammatory Bowel Diseases

Volumn 20, Issue 2, 2014, Pages 251-258

  Brandse, Johannan F ^a   Peters, Charlotte P ^a   Gecse, Krisztina B ^a   Eshuis, Emma J ^a   Jansen, Jeroen M ^b   Tuynman, Hans A ^c   Löwenberg, Mark ^a   Ponsioen, Cyriel Y ^a   Van Den Brink, Gijs R ^a   D'Haens, Geert R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^c Location Alkmaar   (Netherlands)

Author keywords

Adalimumab; Clinical response; Crohn's disease; Infliximab; Retreatment

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; DRUG ANTIBODY; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; FOLLOW UP; HERPES SIMPLEX KERATITIS; HUMAN; INFUSION RELATED REACTION; INJECTION SITE REACTION; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; PATIENT PREFERENCE; PRIORITY JOURNAL; REGISTER; REMISSION; RETREATMENT; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893809447     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000438248.14218.1d     Document Type: Article

References (46)

1. Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
3. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
4. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
7. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
8. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102-1111.
9. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104:760-767.
10. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011;106:674-684.
11. Chaparro M, Panes J, Garcia V, et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis. 2012;18:685-690.
12. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987-995.
13. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
14. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
15. Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a costeffectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509-1520.
16. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:1984-1989.
17. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
18. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther. 2007;25:675-680.
19. Hinojosa J, Gomollon F, Garcia S, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther. 2007;25:409-418.
20. Oussalah A, Babouri A, Chevaux JB, et al. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year singlecentre experience. Aliment Pharmacol Ther. 2009;29:416-423.
21. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
22. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther. 2009;29:527-534.
23. Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an antitumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18:1523-1530.
24. Van Assche G, Vermeire S, Ballet V, et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012;61:229-234.
25. Hoentjen F, Haarhuis BJ, Drenth JP, et al. Elective switching from infliximab to adalimumab in stable Crohn's disease. Inflamm Bowel Dis. 2013; 19:761-766.
26. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92-101.
27. de Silva PS, Nguyen DD, Sauk J, et al. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36: 459-466.
28. Peters CP, Eshuis EJ, Toxopeus F, et al. Real-life experience with adalimumab in 427 Crohn's disease patients in the Netherlands. OP 301, oral presentation presented at UEG Week, Stockholm, 2011.
29. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
30. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
31. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
32. Vavricka SR, Schoepfer AM, Bansky G, et al. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis. 2011;17:1530-1539.
33. World Health Organization. World Health Organization causality assessment method. Available at http://www.whoumc.org/defs.html. Accessed December 21, 2012.
34. Ricart E, Ordas I, Panes J. Anti-TNF antibody therapy in Crohn's disease: the risk of a switch. Gut. 2012;61:169-170.
35. Cullen G. SWITCHing anti-TNF for nonclinical reasons? Think again! Inflamm Bowel Dis. 2012;18:1589-1590.
36. Laharie D, Chanteloup E, Chabrun E, et al. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders. Aliment Pharmacol Ther. 2009;29:1240-1248.
37. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63-70.
38. Ben-Horin S, Mazor Y, Yanai H, et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther. 2012;35: 714-722.
39. Baert FJ, Drobne D, Ballet V, et al. Early trough levels and antibodies predict safety and success of restarting infliximab after long drug holiday. Gastroenterology. 2011;140(Suppl 1):S-62.
40. Chaparro M, Andreu M, Barreiro-de Acosta M, et al. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol. 2012;18:5219-5224.
41. Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012;18:2026-2033.
42. Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007;13:1093-1099.
43. Virkki LM, Valleala H, Takakubo Y, et al. Outcomes of switching anti- TNF drugs in rheumatoid arthritis-a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol. 2011;30:1447-1454.
44. Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNF alpha blocker failure. Biologics. 2012;6:191-199.
45. Paccou J, Solau-Gervais E, Houvenagel E, et al. Efficacy in current practice of switching between anti-tumour necrosis factor- alpha agents in spondyloarthropathies. Rheumatology (Oxford). 2011;50:714-720.
46. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011;70:157-163.